Literature DB >> 10555844

Management of nonfunctioning pituitary adenomas with suprasellar extensions by transsphenoidal microsurgery.

X Zhang1, Z Fei, J Zhang, L Fu, Z Zhang, W Liu, Y Chen.   

Abstract

BACKGROUND: We evaluated the feasibility and therapeutic effectiveness of transsphenoidal microsurgical removal of nonfunctioning pituitary adenomas with suprasellar extensions. The diagnostic modes, surgical technique, and outcome were reviewed in 208 patients with pituitary adenomas extending beyond the sella turcica who were treated by transsphenoidal microsurgery. All patients except three presented with significantly diminished visual acuity and visual field defects.
METHODS: Diagnosis was confirmed by skull X-ray plain films, CT, or MRI scanning. Operations were performed via a transsphenoidal approach under microscope. A subarachnoid catheter was preoperatively inserted in the lumbar cistern, through which saline was slowly injected during operation to increase the intracranial pressure so as to move the suprasellar tumor into the operative field to aid the removal.
RESULTS: In this series, gross total removal of an adenoma in 146 cases (70.2%) and subtotal removal in 50 cases (24.0%) was achieved; partial removal was carried out in the remaining 12 cases (5.8%) of fibrous or dumbbell-shaped adenomas. There were no deaths in this group. Follow-up review (median 3.8 years) in 187 patients revealed that 97.8% of those with preoperative diminished visual acuity had postoperative improvement; 2.2% had no change, and none deteriorated significantly. Among 181 patients with preoperative visual field defects, postoperative improvement was good in 169 (93.4%), and poor in 12 (6.6%). The major complications were diabetes insipidus and cerebrospinal fluid rhinorrhea, which occurred in 13.5% and 4.8% of patients, respectively. The tumors recurred in 12 patients (6.4%) who were considered to have a macroscopically complete removal at surgery. Continuing growth of residual tumors was found in 31 (16.6%) based on visual acuity decrease, visual field defects, and CT or MRI examination. Of the recurrent and residual tumors, 4, 9, 17, and 13 cases belonged to Grades A, B, C, and D, respectively.
CONCLUSIONS: Comparison with transfrontal surgery suggests that these results are as good as those of transfrontal procedures and that the incidence of serious side effects is considerably lower. We consider that the microsurgical removal of pituitary tumors by the transsphenoidal approach is safe and effective even in very large or giant adenomas, since it allows rapid and adequate decompression of the optic nerves and chiasm.

Entities:  

Mesh:

Year:  1999        PMID: 10555844     DOI: 10.1016/s0090-3019(99)00120-2

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  22 in total

1.  The current role of transcranial surgery in the management of pituitary adenomas.

Authors:  Ravindran Pratheesh; Simon Rajaratnam; Krishna Prabhu; Sunithi E Mani; Geeta Chacko; Ari G Chacko
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

2.  Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery.

Authors:  Christoph P Hofstetter; Michael J Nanaszko; Lynn L Mubita; John Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

3.  Volumetric measurement for comparison of the accuracy between intraoperative CT and postoperative MR imaging in pituitary adenoma surgery.

Authors:  C-C Lee; S-T Lee; C-N Chang; P-C Pai; Y-L Chen; T-C Hsieh; C-C Chuang
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

Review 4.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging.

Authors:  M Tosaka; N Sato; J Hirato; H Fujimaki; R Yamaguchi; H Kohga; K Hashimoto; M Yamada; M Mori; N Saito; Y Yoshimoto
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-26       Impact factor: 3.825

Review 6.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

7.  Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Authors:  I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2017-10-27       Impact factor: 5.115

Review 8.  Primary sellar melanocytoma: pathological, clinical and treatment review.

Authors:  L Albano; M Losa; L R Barzaghi; G Spatola; P Panni; M R Terreni; P Mortini
Journal:  J Endocrinol Invest       Date:  2019-12-03       Impact factor: 4.256

9.  Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up.

Authors:  Anthony L D'Ambrosio; Omar N Syed; Bartosz T Grobelny; Pamela U Freda; Sharon Wardlaw; Jeffrey N Bruce
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes.

Authors:  Muhammad Omar Chohan; Ariana M Levin; Ranjodh Singh; Zhiping Zhou; Carlos L Green; Jacob J Kazam; Apostolos J Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.